Enspire DBS Therapy

Enspire operates at the intersection of neuromodulation, medical devices, and stroke rehabilitation. Its core differentiation is not DBS alone, but the pairing of cerebellar deep brain stimulation with structured physical rehabilitation to target recovery of arm motor function after stroke. This places the company in a specialized clinical-development niche distinct from conventional rehabilitation providers and from DBS companies focused on established indications such as Parkinson’s disease or essential tremor. Enspire’s $27.9 million in disclosed funding, including the $10.3 million Series B1 financing on Jan 13, 2026, supports advancement toward pivotal clinical evidence rather than broad commercial deployment. Cleveland Clinic’s participation in the 2023 Series B and 2026 financing provides notable institutional alignment, while Genesys Capital added board representation through Jamie Stiff. The principal strategic test is whether Phase 2/3 results demonstrate durable, clinically meaningful benefit beyond rehabilitation alone and support regulatory adoption.

Enspire’s trajectory reflects a progression from early feasibility research to pivotal clinical development. The company was founded in 2012 and has focused on combining deep brain stimulation with rehabilitation to restore motor function after stroke. A $17.6 million Series B financing on Aug 1, 2023 supported continued development, while the EDEN early-feasibility trial received publication attention in August 2023. On Jan 13, 2026, Enspire added $10.3 million through a Series B1 financing, raising cumulative disclosed funding to $27.9 million. The financing expanded its investor base to include Genesys Capital alongside Cleveland Clinic and JobsOhio, and Jamie Stiff joined the board. The current inflection point is the multicenter pivotal Phase 2/3 trial, which could determine whether the DBS-plus-rehabilitation model advances toward regulatory and commercial milestones. There is no disclosed evidence of layoffs, large-scale hiring, product commercialization, or revenue expansion.